DOI: 10.1055/s-00000030

Der Klinikarzt

References

Baselga J, Faye Dent S, Cortés J. et al.
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA -mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.
J Clin Oncol. 2018
36. (18_suppl)

Download Bibliographical Data

Search in: